Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.3K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

9.8K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

7.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.8K
Negative Regulator Molecules01:23

Negative Regulator Molecules

37.7K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Blood advances·2026
Same author

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

HemaSphere·2026
Same author

The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis.

Expert opinion on investigational drugs·2026
Same author

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

JCO oncology practice·2026

Related Experiment Video

Updated: Dec 6, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.9K

Targeting p53 in chronic lymphocytic leukemia.

Riccardo Moia1, Paola Boggione1, Abdurraouf Mokhtar Mahmoud1

  • 1Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale , Novara, Italy.

Expert Opinion on Therapeutic Targets
|October 5, 2020
PubMed
Summary

TP53 gene disruption predicts poor outcomes in chronic lymphocytic leukemia (CLL). New therapies targeting the p53 pathway offer hope for improving treatment for these high-risk patients.

Keywords:
TP53 targetingBCL2 inhibitorsBCR inhibitorschronic lymphocytic leukemiaprecision medicine

More Related Videos

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.0K
Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH
07:54

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH

Published on: August 19, 2014

17.4K

Related Experiment Videos

Last Updated: Dec 6, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.9K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.0K
Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH
07:54

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH

Published on: August 19, 2014

17.4K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Genomic studies identify molecular predictors for chronic lymphocytic leukemia (CLL) treatment.
  • TP53 disruption is a strong predictor of chemo-refractoriness in CLL, guiding initial treatment decisions.

Purpose of the Study:

  • To review the p53 biological pathway, its alterations, and clinical implications in CLL.
  • To explore therapeutic options for TP53-disrupted CLL patients, including novel agents targeting the p53 pathway.

Main Methods:

  • Review of scientific literature on TP53 pathway, genetic alterations, and therapeutic strategies in CLL.
  • Analysis of current and emerging treatments for TP53-disrupted CLL.
  • Discussion of the role of p53 in CLL pathogenesis and treatment response.

Main Results:

  • TP53 disruption is associated with a less favorable outcome in CLL, even with current treatments like BCR and BCL2 inhibitors.
  • Novel therapeutic strategies aim to circumvent TP53 disruption, restore mutant p53 function, or potentiate wild-type p53 activity.
  • Emerging molecules show potential for improving outcomes in high-risk CLL patients with TP53 abnormalities.

Conclusions:

  • Targeting the p53 pathway is crucial for improving outcomes in TP53-disrupted CLL.
  • Innovative therapies restoring or potentiating p53 function represent a promising advancement in CLL treatment.
  • Further research is needed to confirm the efficacy of these novel agents in CLL patients with TP53 abnormalities.